Successful management of bleeding with recombinant factor VIIa (NovoSeven®) in a patient with burkitt lymphoma and thrombosis of the left femoral and left common iliac veins

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 332-335

  Čulić, Srdana ^a   Kuljis, Dubravka ^a   Armanda, Visnja ^a   Jankovic, Stipan ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Bleeding; Burkitt lymphoma; Recombinant factor VIIa; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; BURKITT LYMPHOMA; CASE REPORT; EPISTAXIS; FEMALE; FEMORAL VEIN; HUMAN; ILIAC VEIN; INGUINAL LYMPH NODE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; THROMBOCYTOPENIA; TISSUE NECROSIS; TREATMENT OUTCOME; VEIN OCCLUSION; VEIN THROMBOSIS;

ADOLESCENT; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; FACTOR VIIA; FEMALE; FEMORAL VEIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ILIAC VEIN; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 34547811417     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20808     Document Type: Article

References (25)

1. Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience. Br J Haematol 2003;120: 660-670.
2. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994;83:1251-1257.
3. Van Ommen CH, Peters M. Venous thromboembolic disease in childhood. Semin Thromb Hemost 2003;29:391-404.
4. Juimo AG, Temdemno AM, Tapko JB, et al. Superior vena cava tumoral thrombosis revealing a Burkitt's lymphoma and a lymphoblastic non-Hodgkin's lymphoma. A case report. Angiology 1997;48:263-268.
5. Ingram L, Rivera GK, Shapiro DN. Superior vena cava syndrome associated with childhood malignancy: Analysis of 24 cases. Med Pediatr Oncol 1990;18:476-481.
6. Windebank K. Childhood lymphoma. Indian J Pediatr 1998;65: 669-680.
7. Sandlund JT, Dowing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Eng J Med 1996;334:1238-1248.
8. Anton N, Massicotte MP. Venous thromboembolism in pediatrics. Semin Vasc Med 2001;1:111-122.
9. Talkad A, Mathews M, Honings D, et al. Reversal of warfarin-induced anticoagulation with factor VIIa prior to rt-PA in acute stroke. Neurology 2005;64:1480-1481.
10. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002;8:CS98-CS100.
11. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79:1495-1500.
12. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2003;137:884-888
13. (Comment in Ann Intern Med 2003; 139: 791;
14. summary for patients in Ann Intern Med 2002; 137: 141.)
15. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003;82: 257-258 (Epub 2003 Mar 8).
16. Chan S, Kong M, Minning DM, et al. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost 2003;1:760-765.
17. Fattorutto M, Tourreau-Pham S, Mazoyer E, et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can J Anaesth 2004;51:672-679.
18. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-1708.
19. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth 2002;49:S11-S25.
20. Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular weight heparin. Br J Haematol 2002;116:178-186.
21. Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004;113:371-378.
22. Čulić S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003;120:909-910.
23. Poon MC. Management of thrombocytopenic bleeding: Is there a role for recombinant coagulation factor VIIa? Curr Hematol Rep 2003;2:139-147.
24. Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004;41: 25-29.
25. Brenner B, Hoffman R, Balashov D, et al. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: An audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005;11:401-410.